“We have helped developed policies at the national level as far as parental leave for residents and fellows, helping to streamline a lot of that process with the American Board of Urology,” says Daniel Igel, MD.
Daniel Igel, MD, discusses his role as the South Central Section representative to the AUA residents and fellows committee. Dr. Igel is one of the chief urology residents at the University of Kansas Medical Center. Next year, he will be pursuing a fellowship in urologic oncology at the University of Texas MD Anderson Cancer Center.
Study evaluates weight management and prostate cancer progression, QOL
June 12th 2024"To me, the most compelling outcome is really the quality-of-life outcomes. General quality of life as well as emotional quality of life improved in the intervention group significantly," says Jill M. Hamilton Reeves, PhD, RD, CSO.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.